Injectable bulking treatment of persistent fecal incontinence in adult patients after anorectal malformations
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Sep 2019 · 1 min read
In brief
In brief
This prospective study of seven adults with anorectal malformations demonstrates that NASHA/Dx injectable bulking therapy significantly reduced fecal incontinence episodes from a mean of 20.7 to 4.3 over two weeks at 18-month follow-up, with improved physical quality of life and no serious adverse events.
Written by the GCMD Library team from the article.
Background/Purpose
Injectable bulking therapy has emerged as a treatment for fecal incontinence (FI), however there are no studies including adult patients with anorectal malformations (ARM). This study aimed to evaluate non-animal stabilized hyaluronic acid with dextranomer (NASHA/Dx) for the treatment of adult ARM patients with persistent FI.
Methods
Seven adults with ARM and incontinence to loose stool at least once weekly and without rectal or mucosal prolapse were treated with anal NASHA/Dx injection. They were evaluated preoperatively, at 6 and 18 months with a bowel function questionnaire and a 2-week bowel diary as well as FIQL and SF-36 quality of life questionnaires.
Results
Before treatment, the mean number of incontinence episodes over 2 weeks was 20.7 (median 16, range 8–52). At 6 months, the corresponding figures were 5.3 (median 4, range 0–19, p = 0.018), and at 18 months the figures were 4.3 (median 2, range 1–20, p = 0.018). An improved physical function in SF-36 from 74.3 at baseline to 86.4 at 6 months was noted (p = 0.04). No serious adverse events occurred.
Conclusions
NASHA/Dx is a promising treatment option for selected adult patients with persistent FI after ARM. Longer follow up of larger patient series and studies on patients in adolescence is needed.
Type of Study
Treatment Study.
Level of Evidence
Level IV.